报价延迟最少15分钟:2025/07/28 18:04 EDT
盘后时段
|
||||
|
12.81 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
12.81
|
|
|
| 价值评估 |
|
盈利(现时/预测)
0.82/-3.12
|
|
企业价值
715.22M
|
| 资产负债 |
|
每股账面净值
6.41
|
| 现金流量 |
|
现金流量率
0.09
|
| 损益表 |
|
收益
36.56M
|
|
每股收益
0.17
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/07/28 18:04 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner. |
